Survey results show that clinicians largely disagree about choices for severe asthma treatment, due primarily to a lack of ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback